Overview
Glutathione is classified as a antioxidant peptide. Detoxification, antioxidant defense, immune support, skin brightening.
Glutathione is the body's master antioxidant — a tripeptide (glutamate-cysteine-glycine) present in every cell. It neutralizes reactive oxygen species, regenerates vitamins C and E, supports Phase II liver detoxification, and modulates immune cell function. Injectable GSH bypasses poor oral bioavailability.
Also known as: GSH, L-Glutathione, Gamma-Glutamylcysteinylglycine, Reduced Glutathione
Category
Antioxidant
Half-Life
2h
Route
SubQ
FDA Status
Not Approved
How Does Glutathione Work?
Glutathione is the body's master antioxidant — a tripeptide (glutamate-cysteine-glycine) present in every cell. It neutralizes reactive oxygen species, regenerates vitamins C and E, supports Phase II liver detoxification, and modulates immune cell function. Injectable GSH bypasses poor oral bioavailability.
At the molecular level, Glutathione operates through pathways characteristic of the Antioxidant class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Glutathione: overview of biosynthesis, regulation, and clinical role
Forman et al. (Mol. Aspects Med.): Comprehensive review of glutathione's role in redox signaling, detoxification, and its depletion in disease states including Parkinson's, liver disease, and cancer.
Evidence: strong[2]Glutathione and immune function
Dröge & Breitkreutz (Proc. Nutr. Soc.): Review demonstrating glutathione's critical role in lymphocyte proliferation, NK cell activity, and overall immune defense.
Evidence: moderate[3]Glutathione for skin lightening: randomized controlled trial
Weschawalit et al. (Clin. Cosmet. Investig. Dermatol.): RCT showing oral glutathione supplementation significantly reduces melanin index and improves skin elasticity and wrinkles.
Evidence: moderate[4]Glutathione depletion in Parkinson's disease substantia nigra
Sian et al.: Early landmark study demonstrating reduced glutathione levels as one of the earliest biochemical changes in Parkinson's disease pathology.
Evidence: strong[5]USP10 from Human Umbilical Cord Mesenchymal Stem Cells-Derived Extracellular Vesicles Mediates SCL7A11 Deubiquitination in Epithelial Cells: A Key to Anti-ferroptosis and Anti-fibrosis in Pulmonary Fibrosis.
A 2026 study found that extracellular vesicles from human umbilical cord mesenchymal stem cells reduced pulmonary fibrosis and ferroptosis in a mouse model. Researchers demonstrated this effect was driven by USP10-mediated deubiquitination and stabilization of the SLC7A11 protein.
Evidence: preclinical[6]Effects and mechanisms of NAD + on lung injury after cardiac arrest and cardiopulmonary resuscitation in swine.
A 2026 study demonstrated that NAD+ administration significantly attenuated lung injury following cardiac arrest and resuscitation in a swine model. Researchers found this effect was likely mediated by suppressing ferroptosis through the modulation of the YAP/ACSL4 signaling pathway.
Evidence: preclinical[7]Combating Cadmium-Induced Neurotoxicity, Oxidative Stress, and Inflammatory Pathways Using DOPA-31, a Dioxopiperidinamide Derivative in an In Vivo Zebrafish Model.
A 2026 preclinical study demonstrated that DOPA-31 mitigated cadmium-induced neurotoxicity in a zebrafish model by reducing oxidative stress and downregulating pro-inflammatory markers. Researchers found the derivative improved motor and cognitive functions while upregulating neuroprotective factors and reducing neuronal damage.
Evidence: preclinical[8]Vaccarin Improves Myocardial Ischemia-Reperfusion Injury by Attenuating Oxidative Stress and Ferroptosis Through Reducing NOX4-Modulated JAK2/STAT3 Pathway Activation.
In a 2026 preclinical study, researchers demonstrated that vaccarin alleviated myocardial ischemia-reperfusion injury in mouse and cellular models. The findings indicated that vaccarin suppressed oxidative stress and ferroptosis by inhibiting the NOX4-driven JAK2/STAT3 signaling pathway.
Evidence: preclinical[9]ZFP36L1 Enhances Microglial Ferroptosis in Ischemic Stroke by Reducing FTO-Mediated N6-Methyladenosine Demethylation of ACSL1 mRNA.
A 2026 study demonstrated that ZFP36L1 promotes microglial ferroptosis and neuroinflammation during ischemic stroke by reducing FTO mRNA stability and increasing ACSL1 expression. Researchers found that silencing ZFP36L1 successfully alleviated cerebral ischemic injury in mouse models.
Evidence: preclinical[10]Ferroptosis in Breast Cancer: Molecular Insights and Therapeutic Strategies.
Targeting ferroptosis exploits metabolic vulnerabilities in breast cancer subtypes and influences the tumor microenvironment, a 2026 review found. The research demonstrated that this iron-dependent cell death mechanism provides a potential strategy to address drug-resistant cancer stem cells.
Evidence: emerging[11]Independent Exposure to the Fungicide Difenoconazole or the Herbicide Tebuthiuron Disrupts Survival, Behavior, and Alters Midgut-Associated Protein Detection in Aedes aegypti Larvae.
A 2026 study found that exposure to the agrochemicals difenoconazole and tebuthiuron reduced survival, altered behavior, and decreased antioxidant enzyme activity in Aedes aegypti larvae. The research demonstrated significant disruptions in midgut protein expression related to tissue organization and stem cell maintenance.
Evidence: preclinical[12]Investigation on the regulatory effects of kaempferol on immune, inflammatory, and antioxidant functions in late laying hens.
A 2026 study demonstrated that kaempferol supplementation reduced hepatic lipid deposition, enhanced antioxidant capacity, and modulated the immune-inflammatory balance in late laying hens. Researchers found it significantly lowered triglycerides and inflammatory cytokines while increasing antioxidant enzyme activity.
Evidence: preclinical[13]Multilayered analysis of cisplatin resistance mechanisms in bladder cancer: from the cell membrane to organelles.
Cisplatin resistance in bladder cancer operates as a multilayered cellular adaptation involving coordinated changes across the cell membrane, cytoplasm, nucleus, and organelles, a 2026 review demonstrated. The study mapped these integrated networks to highlight mechanisms driving treatment failure and disease recurrence.
Evidence: emerging[14]Hyperbaric oxygen therapy and N-acetylcysteine: a redox-dependent interaction.
A 2026 review found that the combined effects of hyperbaric oxygen therapy and N-acetylcysteine are highly context-dependent. The research demonstrated that NAC enhances HBOT during severe oxidative stress but may attenuate its benefits when reactive oxygen species are required for adaptive signaling.
Evidence: emerging[15]Transcriptomic profiling and targeted validation reveal molecular mechanisms of oxygen therapy in high-altitude cerebral injury.
A 2026 study in mice demonstrated that hyperbaric and normobaric oxygen therapies ameliorated high-altitude cerebral injury. The researchers found that these treatments reduced oxidative stress and neuroinflammation by modulating the PI3K-AKT/Nrf2 and TLR4-NF-κB signaling pathways.
Evidence: preclinical[16]Integrative transcriptome and microbiome analysis reveals ferroptosis-driven duodenal damage caused by Ochratoxin A in mice.
A 2026 study in mice demonstrated that Ochratoxin A induces duodenal damage through ferroptosis and gut microbiota dysbiosis. Researchers found that the mycotoxin disrupts redox balance and iron homeostasis, highlighting a microbiota-duodenum axis in intestinal injury.
Evidence: preclinical[17]Network Analysis Identifies Microsomal Glutathione S-Transferase as a Potential Regulator of Oxidative Stress and Proteasome Dysfunction in Human Osteoarthritic Menisci.
Microsomal glutathione S-transferase (MGST1) regulates oxidative stress and proteasome activity in human osteoarthritic menisci, a 2026 study found. In vitro assays demonstrated that inflammatory stress upregulates MGST1, highlighting its role in joint tissue adaptation.
Evidence: preclinical[18]Preclinical evaluation of puerarin for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Puerarin significantly reduced triglycerides, total cholesterol, and LDL cholesterol while improving antioxidant and inflammatory markers in animal models of non-alcoholic fatty liver disease, a 2026 meta-analysis found. The research demonstrated its ability to regulate lipid metabolism and inhibit inflammatory factors.
Evidence: preclinical[19]Kinetically Gated and Self-Limiting Crystallization Enables Allosteric Phototheranostic Nanocrystals.
A 2026 study demonstrated that kinetically gated phototheranostic nanocrystals exhibited strong near-infrared absorption, reactive oxygen species generation, and catalase-like activity. Furthermore, researchers found that these nanocrystals enabled deep-tissue penetration and potent in vivo tumor ablation under irradiation.
Evidence: preclinical[20]Single-nucleus RNA sequencing reveals ferroptosis as a potential contributor to the pathogenesis of focal cortical dysplasia.
A 2026 study demonstrated that ferroptosis and oxidative stress pathways are significantly altered in the brain tissue of patients with focal cortical dysplasia. Transcriptomic and biochemical analyses revealed that these mechanisms potentially contribute to neuronal dysfunction in this drug-resistant epilepsy.
Evidence: emergingSafety Profile
Excellent safety profile. Used clinically for decades. IV and SubQ routes well-tolerated. Rare allergic reactions possible. May reduce effectiveness of some chemotherapy drugs — avoid during cancer treatment without oncologist approval.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site redness | ~5% of users | mild |
| Mild bloating (oral) | ~8% of users | mild |
| Rare allergic reaction | <1% of users | rare |
Sourcing Glutathione for Research
If you're looking to source Glutathione for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Glutathione — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.